Sona Nanotech, Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Sona Nanotech Inc. (SONA.CN) develops biocompatible gold nanorods and nanoparticles for targeted hyperthermia therapy (THT) in cancer treatment; lateral flow diagnostic tests including Gemini and Saliva tests; and biomedical applications such as optical imaging, drug delivery, and multiplex testing platforms. The company manufactures CTAB-free gold nanorods (GNRs) and spherical gold nanoparticles suspended in pure water, enabling precision heat delivery to tumors via near-infrared light activation, alongside custom conjugation services and rapid tests for bovine TB and concussions. Founded in 2014 and headquartered in Halifax, Nova Scotia, Canada, Sona operates primarily in the nanotechnology life sciences sector, targeting oncology, diagnostics, and research markets with North American facilities supporting preclinical and clinical advancement. Recent developments include dosing the first patient in a THT feasibility trial in 2025, reporting an 80% response rate in the first-in-human study, and entering a 2025 research collaboration with BioVaxys Technologies for vaccine development using GNRs. Earlier milestones encompass the 2023 acquisition of Siva Therapeutics to bolster THT for colorectal cancer, manufacturing enhancements for regulatory trials, and positive biocompatibility assessments from the U.S. Nanotechnology Characterization Laboratory.
Company News
Sona Nanotech to Present at the OTC Markets' Life Sciences Virtual Investor Forum On September 17th
Dow rockets higher as Strait of Hormuz stays open, talks eyed
Iran's blockade of the Strait of Hormuz has wiped out a third of global helium supply, and the scramble for secure alternatives has begun
Dow powers higher as oil slump, easing tensions lift stocks
Hims & Hers shares jump as FDA begins review of restricted peptide compounds
Sona Nanotech appoints two oncologists to scientific advisory board
Sona Nanotech appoints two oncologists to scientific advisory board
Sona Nanotech reports immune activation in melanoma trial of heat-based therapy
Alien Metals shares jump 16% as joint ventures advance drilling at two Western Australia precious metal projects
FTSE 100 Live: Aero and defence stocks lead decline as Trump's Iran deadline looms
Sona Nanotech preclinical study shows tumor regression in colorectal cancer model
Sona Nanotech preclinical study shows tumor regression in colorectal cancer model
Why precision oncology may be poised for a reset: a conversation with Sona Nanotech
Sona Nanotech CEO on breakthrough cancer therapy results - ICYMI
Sona Nanotech poised for clinical breakthrough after melanoma study
Sona Nanotech reveals positive response rate in first-in-human THT cancer therapy study
Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
Sona Nanotech advances first-in-human cancer therapy trial
Sona Provides Update on First-In-Human Clinical Trial